A Review on the Impact of Body Mass Index on Outcomes in Pediatric Leukemia

Annalisa Paviglianiti
Department of Hematology and Stem Cell Transplantation, Saint Antoine Hospital, AP-HP, Paris, France

Abstract: In the last decades, adults and pediatric obesity have become a major issue in developed countries. Considerable research has been conducted in patients with acute lymphoblastic (ALL) and myeloid leukemia (AML) with the aim of correlating body mass index (BMI) and outcomes in patients undergoing chemotherapy for hematological diseases. In adults, a high BMI has been associated with increased leukemia-related mortality. Whether a similar effect exists in the pediatric setting remains controversial. Some of the studies detailed in this review have reported no differences in outcomes according to BMI, whilst other reports have described higher treatment-related mortality, increased risk of relapse and death. Although the link between BMI and acute leukemia outcomes is controversial, a large number of studies describe poorer survival rates in children with AML or ALL with higher BMI. On the other hand, being underweight has been associated with higher treatment-related toxicity. Understanding more about the impact of BMI in pediatric leukemia is of utmost importance to provide prompt intervention and improve outcomes.

Keywords: BMI, acute leukemia, AML, ALL, HCT

Introduction
Acute leukemia is one of the most common pediatric cancers. Acute lymphoblastic leukemia (ALL) is rare in infants (less than 1 year old), but becomes more frequent in toddlers and other children, with a peak incidence at the age of 2 to 5 years old. Acute myeloid leukemia (AML) is less frequently observed, representing 15% to 20% of all childhood leukemia and 30% of adolescent leukemia. After a peak during the first 2 years of life, the subsequent low annual incidence of AML slowly increases after the age of 9 years.

Among the factors that could affect prognosis in children with ALL and AML, nutritional status has been largely investigated.

One of the most used means to evaluate the nutritional status is the body mass index (BMI). BMI represents the measure of appropriateness of weight for a given height. It is calculated by dividing weight in kilograms by height in square meters. In growing children, BMI distribution changes significantly according age and gender. Hence, BMI percentiles by age and sex are used to classify the appropriate BMI in children from the age of 2 years old (the use of the BMI chart is not recommended for clinical use before age two years). Patients are classified according to BMI as normal (5th-84th percentile), underweight (<5th percentile), overweight (85th-95th percentile) or obese (>95th percentile) using the Centers for Disease Control and Prevention growth charts for age and gender. Another
Body Mass Index and Acute Lymphoblastic Leukemia

In 2006, a retrospective study reported outcomes, toxicity and pharmacokinetics across four BMI groups of 621 children receiving induction chemotherapy for ALL. Overall survival (OS), event-free-survival (EFS) and relapse incidence were not significantly different through the four BMI groups. Similarly, the authors did not observe differences in toxicities and pharmacokinetics between the groups (Hijiya 2006). In the same year, a more restricted analysis performed on 322 children with ALL reported that obesity at diagnosis was not associated with a decreased OS and EFS (Baillargeon 2006).

The Nordic Society of Pediatric Hematology and Oncology reported a higher risk of osteonecrosis as treatment-related toxicity after chemotherapy in children with ALL who had a high BMI. Twenty-three of the 97 children analyzed experienced osteonecrosis, of whom seven asymptomatic and 10 requiring surgical intervention. A BMI ≥95th percentile was more frequent among children who experienced osteonecrosis (p=0.02) and it was confirmed as an independent risk factor in multivariate analysis (p=0.04) (Niimimäki 2007).

In 2007, the outcomes of 4260 pediatric patients with ALL were studied with the hypothesis that obese children were at higher risk of relapse. The idea was that obese patients received lower doses of chemotherapy, which is normally dosed on body-surface area. In univariate analysis, obesity was associated with worse outcome in patients older than 10 years (HR 1.48, 95% CI 1.07–2.03, p=0.01). When looking separately in patients diagnosed and after the age of 10 years, the effect of obesity was confirmed in patients older than 10 years also in the verification cohort. On the contrary, obesity was not associated with a poor outcome for patients aged less than 10 years. In multivariate analysis, obesity was an independent factor associated with poor outcome (HR for EFS 1.36, 95% CI 1.04–1.77, p=0.02; HR for relapse 1.29, 95% CI 1.02–1.56, p=0.04) (Butturini 2007).

Being overweight or obese at diagnosis was an independent negative prognostic factor for the 5-year EFS in retrospective study conducted in 181 pediatric patients with ALL. A low EFS was observed in obese/overweight who were in intermediate and high-risk groups (relapse risk according ALL-BMF95 trial) than in non-overweight (p=0.02) (Gelete 2011).

Orgel et al reported outcomes of 198 children with B-cell ALL undergoing induction chemotherapy with the
aim of evaluating the impact of BMI on outcome (n=127 lean, n=30 overweight, n=41 obese). They found that the children overweight and obese were at higher risk for a positive minimal residual disease (MRD) after induction chemotherapy (p=0.016). MRD was analyzed also as a continuous variable and the prevalence of positive MRD according BMI percentile was showed. This report first demonstrated that obesity at diagnosis was associated with an increased risk of persistent minimal disease after induction chemotherapy in pediatric ALL. In multivariate analysis, obesity was independently associated with lower EFS (p=0.012). Of note, the cohort consisted of a majority of Hispanic children (n=157), a population especially prone to obesity (Orgel 2014).18

In the same year, 1033 children with standard risk ALL have been reported from the Medical Research Council consortium. No differences were observed in outcomes and relapse incidence among obese and overweight children versus healthy and underweight groups (Aldhafiri 2014).19

In 2015, 762 pediatric patients with B-cell and T-cell ALL were reported with the aim of analyzing the influence of BMI on outcome. Multivariate analysis showed similar OS and EFS across the groups but a higher relapse risk in patients underweight (HR 1.88, 95% CI 1.13–3.13). In addition, a decrease in BMI during the first 32 weeks of treatment was associated with a lower survival (den Hoed 2015).20

The effect of BMI at diagnosis was analyzed on 373 children with B and T-cell ALL. No differences were found according the BMI groups and relapse incidence or EFS. In multivariate analysis, obese patients had worse OS compared with non-obese (p=0.031). MRD levels on day 19 and 46, relapse incidence, EFS and OS were not associated with BMI percentile change between diagnosis and the end of induction (Eissa 2017).21

A retrospective study performed in 103 children with ALL treated at the Children’s Cancer Institute in Lebanon reported a trend showing poor outcomes (death and relapse) in malnourished children (Yazbeck 2016).22

The role of malnutrition has also been explored in a multicenter cohort of Mexican children. The study enrolled 794 newly diagnosed ALL. In multivariate analysis, a high risk of mortality (RR = 2.08, 95% CI 1.08–4.01) was observed in the group of malnourished children with a high-risk ALL (Martin-Trejo 2017).23 More recently, the Mexican inter-institutional group for the identification of the causes of childhood leukemia group has reported outcomes of 1070 children younger than 15 years old who were diagnosed with B and T-cell ALL with the purpose of identifying BMI at diagnosis as a predictor of higher risk of mortality or relapse. Patients were followed for 24 months after diagnosis and were categorized according CDC and WHO classification for BMI. In both cases, when comparing obese to normal and overweight group, significant differences in OS were noticeable (p=0.003 and p=0.01, respectively). However, no association with early relapse was observed according to BMI group (Núñez-Enríquez 2019).24

No statistically significant association was found by the Nordic Society of Pediatric Hematology Oncology between a higher BMI and the risk of pancreatitis in children with ALL (Mogensen 2018).25 More recently, a decrease in BMI percentile during chemotherapy treatment for intermediate-risk pediatric ALL was associated with higher incidence of infectious and febrile episodes (p=0.04 and p=0.006, respectively) (Chaber 2019).26 Furthermore, obesity was reported as a risk factor for adverse events (treatment-requiring hypertension [p=0.0497], insulin-requiring hyperglycemia [p=0.04], recurrent admission-requiring infections [p=0.02] and recurrent febrile neutropenia admissions [p=0.01]) in a cohort of 155 pediatric patients during pre-maintenance chemotherapy for ALL (Meenan 2019).27

In addition, published research suggests that weight gain during induction chemotherapy is associated with obesity at the end of the treatment, but the impact of this change in weight on outcomes is not known.28–31 Daily body weight measurement30 is one of the preventive measures to take into consideration to avoid the excess body gain. However, other pre-emptive measures should be considered in the future analysis. Table 1 resumes the main outcomes according to studies on BMI and ALL reported in the literature (Table 1).

Overall, the reported studies support the existence of an adverse association between a higher BMI and increased relapse incidence and mortality in pediatric patients with ALL. One could hypothesize a variation in chemotherapy metabolism in the obese, as suggested from preclinical studies, but prospective trials have not found such differences in ALL pediatric patients. Furthermore, whether treatment with glucocorticoids has a long-lasting influence on obesity in pediatric ALL survivors is not well established. Previous studies report a pattern of weight changes in patients with ALL during therapy, due to corticosteroid exposure and related insulin resistance.32
Table 1 ALL and BMI

<table>
<thead>
<tr>
<th>References</th>
<th>n</th>
<th>ALL Subtype</th>
<th>Chemotherapy Regimens</th>
<th>BMI Groups Definition</th>
<th>Age Range, Y</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nunez-Enriquez JC, BMC Cancer 2019</td>
<td>1070</td>
<td>B cell = 931</td>
<td>Not mentioned</td>
<td>WHO</td>
<td>0–15</td>
<td>Overweight and obese had higher early mortality</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Biphenotypic = 37</td>
<td></td>
<td>CDC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>T cell = 102</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Martín-Trejo JA, Leuk Lymph 2017</td>
<td>794</td>
<td>B cell =706</td>
<td>Not mentioned</td>
<td>WHO</td>
<td>0–17</td>
<td>High risk of dying in malnourished children with a high-risk ALL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T cell=88</td>
<td></td>
<td>CDC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eissa HM, Blood Cancer J 2017</td>
<td>373</td>
<td>B cell=310</td>
<td>Total XV protocol</td>
<td>CDC</td>
<td>2–17.9</td>
<td>No differences in relapse incidence and EFS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T cell=63</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Niinimaki RA, JCO 2007</td>
<td>97</td>
<td>All B cell precursor</td>
<td>ALL-NSPHO 86, 92, 2000</td>
<td>Finnish norms</td>
<td>1–15</td>
<td>High BMI associated with radiographic osteonecrosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>den Hoed MAH, Haematologica 2015</td>
<td>703</td>
<td>B cell=573</td>
<td>DCOG - ALL19</td>
<td>WHO</td>
<td>2–17</td>
<td>Higher relapse risk in underweight, but similar OS and EFS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T cell=130</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hijiya N, Blood 2006</td>
<td>621</td>
<td>B cell=516</td>
<td>Total XII, XIIIA,</td>
<td>CDC</td>
<td>1.01–18.08</td>
<td>EFS, OS relapse incidence and toxicities did not differ among the 4 BMI groups</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>XIIIB, XIV</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Butturini AM, JCO 2007</td>
<td>4260</td>
<td>B cell= 473*</td>
<td>CCG-1922, 1891,</td>
<td>CDC</td>
<td>2–19.99</td>
<td>Higher EFS and relapse incidence in ≥10 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1882, 1901</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gelelete CB, Obesity, 2011</td>
<td>181</td>
<td>B cell=144</td>
<td>BMF90, BMF95,</td>
<td>WHO</td>
<td>≤10–18</td>
<td>5-y EFS lower in overweight/obese</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>BMF2002</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yazbeck N, J Pediatr Oncol 2016</td>
<td>103</td>
<td>B and T cell</td>
<td>Not mentioned</td>
<td>WHO</td>
<td>0–17</td>
<td>Trend showing worse outcomes in malnourished children (death and relapse)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orgel E, Blood 2014</td>
<td>198</td>
<td>All B cell precursor</td>
<td>CCG-1991, 1961;</td>
<td>CDC</td>
<td>1 21</td>
<td>Obesity at induction associated with greater risk of persistent MRD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>AALL0331, 0932,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>08P1, 0232, 1131</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>WFLs 1 y</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baillargeon J, J Pediatr Oncol 2006</td>
<td>322</td>
<td>B cell</td>
<td>Not mentioned</td>
<td>WHO</td>
<td>0–18</td>
<td>Obesity not associated with decreased OS or EFS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aldhafiri FK, J Pediatr Hematol Oncol 2014</td>
<td>1033</td>
<td>All B cell precursor</td>
<td>UK ALL-X</td>
<td>BMI according international survey thresholds</td>
<td>2–14.9</td>
<td>Relapse incidence was no different among the 4 groups</td>
</tr>
</tbody>
</table>

Note: *Data available for pts ≥10 years.

Abbreviations: BMI, body mass index; WHO, World Health Organisation; CDC, Centers of Disease Control; ALL, acute lymphoblastic leukemia; NPSHO, Nordic Society of Pediatric Hematology and Oncology; OS, overall survival; EFS, event-free survival; DCOG, Dutch Childhood Oncology Group; CCG, Children’s Cancer Group; WFL, weight-for-length; MRD, minimal residual disease.
Biological mechanisms that modify the risk of obesity by gender and age at diagnosis have been proposed (insulin growth factor, leptin) but remain speculative and longer follow up prospective studies are needed.

**BMI and Acute Myeloid Leukemia**

In 2005, poor outcome in obese and underweight children treated in the Children Cancer Group (CCG) 2961 was first reported. Both underweight and overweight children with AML had increased treatment toxicities and decreased OS. Survival and EFS at 3 years were significantly lower in obese children (p<0.001 and p=0.009, respectively). Inferior outcomes were due to treatment-related mortality in the first months of chemotherapy (Lange 2005).

Inaba et al detailed outcomes of 314 children with AML enrolled in four St. Jude protocols and grouped according to BMI. The 5-year OS of overweight/obese was lower than that of patients with healthy weight (46.5% versus 67.1%, P <.001). In a multivariable analysis, patients with normal BMI had the best survival rate among the 3 groups (p=0.01). When BMI was considered as a continuous variable, patients with lower or higher BMI percentiles had worse survival (p=0.03). Underweight and overweight/obese patients had a significantly higher cumulative incidence of treatment-related mortality, especially due to infection (p=0.009) (Inaba 2012).

Subsequently, the analysis of combined data from the CCG-2891, CCG-2941, CCG-2961, and AAML03P1 trials was reported. The data-set included 1840 patients, 238 from 16 to 20 years old, and 1602 aged less than 16 years old. In multivariate model, being overweight was independently associated with treatment-related mortality (HR = 2.18, 95% CI = 1.42–3.36, P <.001), poorer OS (HR = 1.56, 95% CI = 1.21–2.03, P <.001) and EFS (HR = 1.36, 95% CI = 1.08–1.73, P=0.011) (Canner 2013).

In contrast, being overweight or obese was not associated with poor outcomes in a cohort of 58 Taiwanese children with AML. Despite the limited number of patients, this single-center experience reported comparable OS and EFS among the 3 BMI groups (underweight, n=3, healthy, n=40, overweight, n=15) (Chen 2015).

The Northern Society of Pediatric Hematology and Oncology described outcomes and toxicities after chemotherapy protocol AML 2004 and reported also the impact of BMI in 318 children. In this cohort, being overweight was associated with a higher risk of being bed-ridden and requiring supplemental oxygen (HR = 1.9, 95% CI = 1.0–3.5, P=0.04). For children aged 10 to 17 years old, being overweight was associated with a trend for superior EFS (59% versus 40%, p=0.09) and OS (78% versus 56%, p=0.06) compared to healthy weight children. On the contrary, in children aged 2 to 9 years EFS and OS were not significantly different when comparing overweight and healthy weight. These data suggested a possible different pharmacokinetics of chemotherapy drugs in adolescents and children (Løhmann 2016).

Recently, the association of BMI and outcome was in a large multicenter cohort of 867 children with AML. The study included children diagnosed in the last twenty years and correlated cytogenetic abnormalities with BMI also. No difference in relapse risk, TRM; 5-year OS was reported across the four BMI groups. Importantly, obese patients had a higher frequency of t(8;21) and inv(16) (Løhmann 2019). Table 2 shows outcomes according to studies on BMI and AML (Table 2).

As for pediatric ALL, the included studies reported an association of poorer OS in AML pediatric patients with a higher BMI. Conversely, a higher toxicity was observed in several of these reports. Therefore, on could assume that poor survival is due to greater treatment-related mortality rather than relapse in these acute leukemia subtypes. Nevertheless, the pathophysiology of the association between higher BMI and AML pediatric outcomes is probably multifactorial and still need to be clarified throughout epidemiological and biological studies.

**BMI and Acute Leukemia Undergoing Hematopoietic Cell Transplantation**

BMI may have an impact on outcome after allogeneic hematopoietic cell transplantation (HCT) (Gleimer 2015). Obesity and undernourishment have been associated with complications and inferior outcomes after HCT in pediatric patients, but the majorities of the studies are heterogeneous and not exclusive to acute leukemia. Bulley et al reported a heterogeneous cohort of 325 children, including 192 with acute leukemia, undergoing HCT. This single-center study, comprising different stem cell sources and conditioning regimens, demonstrated inferior OS in overweight patients compared to normal BMI (p=0.02) (Bulley 2008).

No association between poor outcomes and being obese or undernourished was found in a cohort of 200 children (of whom ALL, n=113; AML, n=55) who underwent umbilical cord blood transplantation (Pine 2011).
The impact of pre-HCT BMI together on outcomes has been analyzed in 733 patients (ALL, n=395; AML, n=189; other hematological malignancies, n=145) aged 2 to 18 years. The BMI 5th-24th percentile group had lower EFS (p=0.01) and higher relapse (p=0.003) at day +100 post-HCT (Hoffmeister 2013).

Aplenc and colleagues reported no difference in OS after HCT according to four BMI classes among children in a large retrospective study. The analysis included 3687 patients aged 2 to 19 years with AML, ALL, chronic myeloid leukemia and myelodysplastic syndrome. Obese children had less relapse after HCT but higher transplant-related mortality (Aplenc 2014).

More recently, the impact of BMI has been reported in a retrospective study including 855 children with acute leukemia (ALL, n=577; AML, n=278) undergoing single umbilical cord blood transplantation. In multivariate analysis, a BMI <5th percentile was associated with higher incidence of acute grade II to IV graft-versus-host disease compared with normal-BMI patients (p = 0.006) (Paviglianiti 2018).

**Conclusion**

The association between BMI and acute leukemia outcomes after chemotherapy and/or HSCT remains controversial. Being at either extreme of the index (underweight or obese) is associated with worse outcomes and toxicities. The inclusion of different chemotherapy protocols, leukemia subtypes analyzed, diet habits and differences between high and low-income countries are some of the factors that could lead to misinterpretation of the data.

However, BMI remains an important tool to characterize the nutritional status of children with AML or ALL before chemotherapy treatment or HCT. Nutritional evaluation should be taken into account before any type of cancer treatment. Inappropriate dose of chemotherapy drugs due to obesity condition or for being undernourished might be associated to poorer prognosis in pediatric AML and ALL. However, the biology of adipose tissue, hormone and genetic interactions needs to be better understood. BMI is only a surrogate measure of body fat because it measures excess weight rather than excess fat. In other words, BMI does not distinguish between excess fat, muscle, or bone mass, nor does it provide any indication of the distribution of fat among individuals.

Understanding the prognostic impact of obesity on pediatric cancer outcomes has both clinical and public health implications for preventive intervention that could improve outcomes. The higher incidence of obesity worldwide solicits for prospective investigation to provide the prompt intervention and improving outcomes of children with acute leukemia.

### Table 2 AML and BMI

<table>
<thead>
<tr>
<th>References</th>
<th>n</th>
<th>Chemotherapy Regimens</th>
<th>BMI Groups Definition</th>
<th>Age Range, Y</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lohmann DJ, Haematologica 2016</td>
<td>318</td>
<td>NOPHO-AML 2004</td>
<td>WHO</td>
<td>0–17</td>
<td>Overweight associated with requirement in supplemental oxygen</td>
</tr>
<tr>
<td>Chen SH, Int J Hematol 2015</td>
<td>58</td>
<td>TPOG-AML-97</td>
<td>WHO</td>
<td>0–18</td>
<td>Overweight and aged 10–17 higher risk of grade 3–4 toxicity</td>
</tr>
<tr>
<td>Canner J, Cancer 2013</td>
<td>1840</td>
<td>CCG-2891, 2941, 2961, AAML03PI</td>
<td>WFLS 1 y CDC</td>
<td>0.01–20.9</td>
<td>5-y EFS was not significantly different among BMI groups</td>
</tr>
<tr>
<td>Inaba H, Cancer 2012</td>
<td>314</td>
<td>AMB87, 91, 9, 02</td>
<td>CDC</td>
<td>2–19.9</td>
<td>Overweight had higher risk for TRM, EFS and OS</td>
</tr>
<tr>
<td>Lange BJ, JAMA 2005</td>
<td>768</td>
<td>CCG-2961</td>
<td>CDC</td>
<td>0.01–20.9</td>
<td>Lower 5-y OS in children overweight and obese</td>
</tr>
<tr>
<td>Lohmann DJ, Cancer Med 2019</td>
<td>867</td>
<td>AAML0531,15; COG9421,16; NOPHO-AML 2004,17 DB AML-01,18; NOPHO-DBH AML 2012</td>
<td>WHO</td>
<td></td>
<td>Higher TRT in underweight</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index; WHO, World Health Organization; CDC, Centers of Disease Control; NOPHO, Nordic Society for Pediatric Hematology and Oncology; OS, overall survival; EFS, event-free survival; DCOG, Dutch Childhood Oncology Group; CCG, Children’s Cancer Group; WFL, weight-for-length; TPOG, Taiwan Pediatric Oncology protocol.
Acknowledgments

The author would like to thank Fernanda Volt, MT, MSc (Eurocord, Paris) for critical reading of this manuscript.

Disclosure

The author reports no conflicts of interest in this work.

References


---

**Journal of Blood Medicine**

**Publish your work in this journal**

The Journal of Blood Medicine is an international, peer-reviewed, open access journal publishing laboratory, experimental and clinical aspects of all aspects pertaining to blood based medicine including but not limited to: Transfusion Medicine; Blood collection, Donor issues, Transmittable diseases, and Blood banking logistics; Immunohematology; Artificial and alternative blood based therapeutics; Hematology; Biotechnology/nanotechnology of blood related medicine; Legal aspects of blood medicine; Historical perspectives. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.